Guangdong Marubi Biotechnology Management
Management criteria checks 3/4
Guangdong Marubi Biotechnology's CEO is Huaiqing Sun, appointed in Jan 2012, has a tenure of 13.42 years. directly owns 72.72% of the company’s shares, worth CN¥14.24B. The average tenure of the management team and the board of directors is 13.4 years and 4.6 years respectively.
Key information
Huaiqing Sun
Chief executive officer
CN¥2.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 13.4yrs |
| CEO ownership | 72.7% |
| Management average tenure | 13.4yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
If EPS Growth Is Important To You, Guangdong Marubi Biotechnology (SHSE:603983) Presents An Opportunity
Apr 01
A Look At The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)
Mar 16Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital
Dec 25Calculating The Fair Value Of Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983)
Dec 09Is Now The Time To Put Guangdong Marubi Biotechnology (SHSE:603983) On Your Watchlist?
Nov 22Market Participants Recognise Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Earnings Pushing Shares 27% Higher
Sep 26Guangdong Marubi Biotechnology's (SHSE:603983) Promising Earnings May Rest On Soft Foundations
Aug 30Investors Could Be Concerned With Guangdong Marubi Biotechnology's (SHSE:603983) Returns On Capital
Jun 19Guangdong Marubi Biotechnology (SHSE:603983) Has A Pretty Healthy Balance Sheet
May 29Are Guangdong Marubi Biotechnology Co., Ltd. (SHSE:603983) Investors Paying Above The Intrinsic Value?
May 07Guangdong Marubi Biotechnology Co., Ltd.'s (SHSE:603983) Share Price Matching Investor Opinion
Mar 27Guangdong Marubi Biotechnology (SHSE:603983) Will Be Hoping To Turn Its Returns On Capital Around
Feb 29CEO
Huaiqing Sun (56 yo)
Mr. Huaiqing Sun is Chairman and Chief Executive Officer of Guangdong Marubi Biotechnology Co., Ltd. from January 18, 2012.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 13.4yrs | CN¥2.11m | 72.72% CN¥ 14.2b | |
| CFO & Director | 13.4yrs | CN¥2.41m | no data | |
| Chief Marketing Officer & Director | no data | CN¥2.14m | no data | |
| Board Secretary | 2.8yrs | CN¥685.10k | no data | |
| Head of Accounting Department & Accounting Supervisor | no data | no data | no data |
Experienced Management: 603983's management team is seasoned and experienced (13.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 13.4yrs | CN¥2.11m | 72.72% CN¥ 14.2b | |
| CFO & Director | no data | CN¥2.41m | no data | |
| Chief Marketing Officer & Director | 7.1yrs | CN¥2.14m | no data | |
| Independent Director | 2.1yrs | CN¥112.40k | no data | |
| Director | 4.3yrs | CN¥1.08m | no data | |
| Director | 4.3yrs | CN¥885.40k | no data | |
| Supervisor | 5.5yrs | no data | no data | |
| Chairman of the the Supervisory Board | 4.6yrs | no data | no data |
Experienced Board: 603983's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 13:02 |
| End of Day Share Price | 2025/06/05 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Guangdong Marubi Biotechnology Co., Ltd. is covered by 21 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lei Yang | CGS International |
| Lei Yang | China Galaxy International Securities (Hong Kong) |
| Zhuonan Xu | China International Capital Corporation Limited |